Impact of Digital Technologies on Clinical Care for Adults with Cystic Fibrosis

Abstract

The coronavirus disease 2019 pandemic accelerated the implementation of digital technologies, which have now become embedded as essential tools for the management of chronic disease, including cystic fibrosis (CF). Despite subsequent easing of restrictions and because of improved clinical stability resulting from the introduction of highly effective modulator therapy, digital technologies including video and telephone consultations and remote monitoring are likely to remain integral to the future delivery of CF health care. In this article, we explore some of the key developments in digital technologies, barriers to their adoption, and how the CF community is likely to embrace lessons learned from the recent pandemic to help modernize and reshape the future of CF care.

Keywords

cystic fibrosis - COVID-19 - video consultation - telemedicine - adherence

Publikationsverlauf

Artikel online veröffentlicht:
19. Dezember 2022

• References

• 1 Keesara S, Jonas A, Schulman K. Covid-19 and health care's digital revolution. N Engl J Med 2020; 382 (23) e82
• 2 Peckham D. Electronic patient records, past, present and future. Paediatr Respir Rev 2016; 20 (suppl): 8-11
• 3 Costa RLF, Costa RF, Gonçalves CP, Cohen RWF, Santana NN. Telemedicine of patients with cystic fibrosis during the COVID-19 pandemic. Rev Paul Pediatr 2022; 40: e2021118 (In engpor).
• 4 Rodkjær L, Jeppesen M, Schougaard L. Management of cystic fibrosis during COVID-19: patient reported outcomes based remote follow-up among CF patients in Denmark—a feasibility study. J Cyst Fibros 2022; 21 (02) e106-e112
• 5 Compton M, Soper M, Reilly B. et al. A feasibility study of urgent implementation of cystic fibrosis multidisciplinary telemedicine clinic in the face of covid-19 pandemic: single-center experience. Telemed J E Health 2020; 26 (08) 978-984
• 6 Middleton PG, Mall MA, Dřevínek P. et al; VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019; 381 (19) 1809-1819
• 7 Heijerman HGM, McKone EF, Downey DG. et al; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019; 394 (10212): 1940-1948
• 8 Barry PJ, Mall MA, Álvarez A. et al; VX18-445-104 Study Group. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. N Engl J Med 2021; 385 (09) 815-825
• 9 Peckham D, Etherington C, White H. et al. The development and deployment of integrated electronic care records in a regional adult and paediatric cystic fibrosis unit. J Cyst Fibros 2014; 13 (06) 681-686
• 10 Hussain SA, Sezgin E, Krivchenia K, Luna J, Rust S, Huang Y. A natural language processing pipeline to synthesize patient-generated notes toward improving remote care and chronic disease management: a cystic fibrosis case study. JAMIA Open 2021; 4 (03) ooab084
• 11 White H, Shaw N, Denman S, Pollard K, Wynne S, Peckham DG. Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis. Eur Respir J 2017; 49 (03) 1600987
• 12 Wainwright CE, Tullis E. Electronic care records—can they fulfil their promise?. J Cyst Fibros 2014; 13 (06) 608-609
• 13 Eakin MN, Riekert KA. The impact of medication adherence on lung health outcomes in cystic fibrosis. Curr Opin Pulm Med 2013; 19 (06) 687-691
• 14 Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011; 140 (02) 425-432
• 15 Ball R, Southern KW, McCormack P, Duff AJA, Brownlee KG, McNamara PS. Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time. J Cyst Fibros 2013; 12 (05) 440-444
• 16 Raywood E, Douglas H, Kapoor K. et al. Protocol for Project Fizzyo, an analytic longitudinal observational cohort study of physiotherapy for children and young people with cystic fibrosis, with interrupted time-series design. BMJ Open 2020; 10 (10) e039587
• 17 Arden MA, Hutchings M, Whelan P. et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub. Pilot Feasibility Stud 2021; 7 (01) 1
• 18 Hoo ZH, Totton N, Waterhouse S. et al. Real-world adherence among adults with cystic fibrosis is low: a retrospective analysis of the CFHealthHub Digital Learning Health System. Chest 2021; 160 (06) 2061-2065
• 19 Wood J, Mulrennan S, Hill K, Cecins N, Morey S, Jenkins S. Telehealth clinics increase access to care for adults with cystic fibrosis living in rural and remote Western Australia. J Telemed Telecare 2017; 23 (07) 673-679
• 20 Gur M, Nir V, Teleshov A. et al. The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: a pilot study. J Telemed Telecare 2017; 23 (04) 489-493
• 21 Gifford AH, Ong T, Dowd C. et al. Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs. J Cyst Fibros 2021; 20 (3, Suppl 3): 9-13
• 22 Albon D, Thomas L, Hoberg L. et al; CF Learning Network telehealth iLab working group. Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting. BMJ Open Qual 2022; 11 (02) e001844
• 23 Etherington C, Conway S, Peckham D. The role of electronic patient records (EPR) in improving service efficiency and clinical performance in a regional adult UK centre. J Cyst Fibros 2011; 10 (01) S96
• 24 Spoletini G, Campbel C, Etherington C. et al. Evolving cystic fibrosis care during COVID-19: a single-centre experience. J Cyst Fibros 2022; 21 (01) S53
• 25 Perkins RC, Davis J, NeSmith A. et al. Favorable clinician acceptability of telehealth as part of the cystic fibrosis care model during the COVID-19 pandemic. Ann Am Thorac Soc 2021; 18 (09) 1588-1592
• 26 Solomon GM, Bailey J, Lawlor J. et al. Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic. J Cyst Fibros 2021; 20 (3, suppl 3): 41-46
• 27 Beşer ÖF, Karaboğa EPU, Hepkaya E. et al. The role of telehealth services in children with cystic fibrosis during coronavirus disease 2019 outbreak. Telemed J E Health 2022; 28 (06) 832-837
• 28 Edmondson C, Westrupp N, Seddon P. et al. The feasibility of home monitoring of young people with cystic fibrosis: results from CLIMB-CF. J Cyst Fibros 2022; 21 (01) 70-77
• 29 Hendra K, Neemuchwala F, Chan M, Ly NP, Gibb ER. Patient and provider experience with cystic fibrosis telemedicine clinic. Front Pediatr 2021; 9: 784692
• 30 Hatziagorou E, Toulia I, Avramidou V, Kampouras A, Tsara V, Tsanakas J. Change in CF care during COVID-19 pandemic: single-center experience in a middle-income setting. Pediatr Pulmonol 2021; 56 (09) 3065-3067
• 31 Cox NS, Alison JA, Rasekaba T, Holland AE. Telehealth in cystic fibrosis: a systematic review. J Telemed Telecare 2012; 18 (02) 72-78
• 32 Hamilton JL, Snuggerud AE, Meihls SM, Toledo H, Stewart J. Quality improvement and rapid PDSA cycles to maintain routine surveillance of pulmonary pathogens during the COVID-19 pandemic in a pediatric cystic fibrosis clinic. J Pediatr Nurs 2022; 63: 131-135
• 33 Ong T, Van Citters AD, Dowd C. et al. Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. J Cyst Fibros 2021; 20 (3, Suppl 3): 57-63
• 34 Muhlebach MS, Cunningham F, LiPuma JJ, Zhou JJ, Saiman L. Impact of the SARS-CoV-2 pandemic on cystic fibrosis centres and care: survey results from US centres. ERJ Open Res 2021; 7 (04) 00249-2021
• 35 Franciosi AN, Wilcox PG, Quon BS. Cystic fibrosis respiratory microbiology monitoring during a global pandemic: lessons learned from a shift to telehealth. Ann Am Thorac Soc 2022; 19 (03) 498-500
• 36 Bouzek DC, Ren CL, Thompson M, Slaven JE, Sanders DB. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis. Pediatr Pulmonol 2022; 57 (07) 1709-1716
• 37 Paynter A, Khan U, Heltshe SL, Goss CH, Lechtzin N, Hamblett NM. A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis. J Cyst Fibros 2022; 21 (01) 78-83
• 38 Bell JM, Sivam S, Dentice RL. et al. Quality of home spirometry performance amongst adults with cystic fibrosis. J Cyst Fibros 2022; 21 (01) 84-87
• 39 Morimoto Y, Takahashi T, Sawa R. et al. Web portals for patients with chronic diseases: scoping review of the functional features and theoretical frameworks of telerehabilitation platforms. J Med Internet Res 2022; 24 (01) e27759
• 40 Milligan CM, Pollard K, Watson R. et al. Physiotherapist-led online exercise session for people with cystic fibrosis (CF) during the COVID-19 pandemic: a service evaluation. Thorax 2021; 76 (01) A134
• 41 Tomlinson OW, Shelley J, Trott J, Bowhay B, Chauhan R, Sheldon CD. The feasibility of online video calling to engage patients with cystic fibrosis in exercise training. J Telemed Telecare 2020; 26 (06) 356-364
• 42 Hillen B, Simon P, Schlotter S. et al. Feasibility and implementation of a personalized, web-based exercise intervention for people with cystic fibrosis for 1 year. BMC Sports Sci Med Rehabil 2021; 13 (01) 95
• 43 Cox NS, Alison JA, Button BM, Wilson JW, Holland AE. Assessing exercise capacity using telehealth: a feasibility study in adults with cystic fibrosis. Respir Care 2013; 58 (02) 286-290
• 44 Huhn S, Axt M, Gunga HC. et al. The impact of wearable technologies in health research: scoping review. JMIR Mhealth Uhealth 2022; 10 (01) e34384
• 45 Shelley J, Fairclough SJ, Knowles ZR. et al. A formative study exploring perceptions of physical activity and physical activity monitoring among children and young people with cystic fibrosis and health care professionals. BMC Pediatr 2018; 18 (01) 335
• 46 Curran M, Tierney A, Collins L. et al. Accuracy of the ActivPAL and Fitbit Charge 2 in measuring step count in cystic fibrosis. Physiother Theory Pract 2021; 8: 1-11
• 47 Gaynor M, Sawyer A, Jenkins S, Wood J. Variable agreement between wearable heart rate monitors during exercise in cystic fibrosis. ERJ Open Res 2019; 5 (04) 00006-2019
• 48 Savi D, Graziano L, Giordani B. et al. New strategies of physical activity assessment in cystic fibrosis: a pilot study. BMC Pulm Med 2020; 20 (01) 285
• 49 G S, L G, K P, et al. Dose adjustments of elexacaftor/tezacaftor/ivacaftor in response to mental health side effects in adults with cystic fibrosis. J Cyst Fibros 2022; (e-pub ahead of print)
• 50 Gonska T. The sweat chloride test has lived up to the changes in CF care. J Cyst Fibros 2022; 21 (03) 381-382
• 51 Choi DH, Kitchen GB, Jennings MT, Cutting GR, Searson PC. Out-of-clinic measurement of sweat chloride using a wearable sensor during low-intensity exercise. NPJ Digit Med 2020; 3: 49
• 52 Choi DH, Thaxton A, Jeong IC. et al. Sweat test for cystic fibrosis: wearable sweat sensor vs. standard laboratory test. J Cyst Fibros 2018; 17 (04) e35-e38
• 53 Tabasum H, Gill N, Mishra R, Lone S. Wearable microfluidic-based e-skin sweat sensors. RSC Advances 2022; 12 (14) 8691-8707
• 54 Relf R, Willmott A, Flint MS, Beale L, Maxwell N. Reliability of a wearable sweat rate monitor and routine sweat analysis techniques under heat stress in females. J Therm Biol 2019; 79: 209-217
• 55 Timpel P, Oswald S, Schwarz PEH, Harst L. Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: an umbrella review of systematic reviews and meta-analyses. J Med Internet Res 2020; 22 (03) e16791
• 56 Scully KJ, Sherwood JS, Martin K. et al. Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis. J Clin Endocrinol Metab 2022; 107 (04) e1444-e1454
• 57 Gojsina B, Minic P, Todorovic S, Soldatovic I, Sovtic A. Continuous glucose monitoring as a valuable tool in the early detection of diabetes related to cystic fibrosis. Front Pediatr 2021; 9: 659728
• 58 Marks BE, Williams KM, Sherwood JS, Putman MS. Practical aspects of diabetes technology use: continuous glucose monitors, insulin pumps, and automated insulin delivery systems. J Clin Transl Endocrinol 2021; 27: 100282
• 59 Ahmed R, Greenfield M, Morley CP, Desimone M. Satisfaction and concerns with telemedicine endocrine care of patients with cystic fibrosis. Telemed Rep 2022; 3 (01) 93-100
• 60 Shimmin D, Mansfield M, Taylor K. et al. Early experience of flash glucose monitoring using the Freestyle Libre System in adults with Cystic Fibrosis-Related Diabetes (CFRD) attending a large regional UK centre. J Cyst Fibros 2000; 19 (02) S26
• 61 Frost F, Dyce P, Nazareth D, Malone V, Walshaw MJ. Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes. J Cyst Fibros 2018; 17 (06) 798-803
• 62 Jaclyn D, Andrew N, Ryan P. et al. Patient and family perceptions of telehealth as part of the cystic fibrosis care model during COVID-19. J Cyst Fibros 2021; 20 (03) e23-e28
• 63 Thee S, Stahl M, Fischer R. et al. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulm Med 2021; 21 (01) 131
• 64 Lang RL, Wilson C, Stockton K, Russell T, Johnston LM. CyFiT telehealth: protocol for a randomised controlled trial of an online outpatient physiotherapy service for children with cystic fibrosis. BMC Pulm Med 2019; 19 (01) 21
• 65 Nash EF, Choyce J, Carrolan V. et al. A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis. Ther Adv Respir Dis 2022; 16: 17 534666211070133
• 66 Van Citters AD, Dieni O, Scalia P. et al. Barriers and facilitators to implementing telehealth services during the COVID-19 pandemic: a qualitative analysis of interviews with cystic fibrosis care team members. J Cyst Fibros 2021; 20 (3, Suppl 3): 23-28
• 67 Albon D, Van Citters AD, Ong T. et al. Telehealth use in cystic fibrosis during COVID-19: association with race, ethnicity, and socioeconomic factors. J Cyst Fibros 2021; 20 (3, Suppl 3): 49-54
• 68 Garcia B, Christon L, Gray S. MUSC Adult CF Program. In the south, if you give us lemons, we will make you lemonade. J Cyst Fibros 2020; 19 (05) 842-843